Resolution of refractory no-reflow with intracoronary epinephrine

Catheter Cardiovasc Interv. 2002 Nov;57(3):305-9. doi: 10.1002/ccd.10303.

Abstract

Refractory no-reflow is associated with adverse outcomes in patients undergoing percutaneous coronary intervention. Charts were reviewed to identify 29 consecutive patients in whom intracoronary epinephrine was administered for refractory no-reflow. The effects of intracoronary epinephrine on coronary flow (TIMI grade), cardiac rhythm, and systolic blood pressure in the cardiac catheterization laboratory were assessed. Administration of intracoronary epinephrine (mean dose, 139 +/- 189 microg) resulted in significant improvement in coronary flow. After administration, TIMI 3 flow was established in 69% of patients. Overall, TIMI flow significantly increased (mean TIMI flow form 1.0 +/- 1.0 to 2.66 +/- 0.55; P = 0.0001). Intracoronary epinephrine resulted in significant but tolerable increase in heart rate (72 +/- 19 to 86 +/- 26 beats/min; P = 0.009), but no cases of acute dysrhythmia. These findings indicate that intracoronary epinephrine may exert salutary effects in patients suffering refractory no-reflow following elective or acute coronary interventions.

MeSH terms

  • Abciximab
  • Acute Disease
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal / therapeutic use
  • Anticoagulants / therapeutic use
  • Blood Flow Velocity / drug effects*
  • Blood Flow Velocity / physiology*
  • Blood Pressure / drug effects
  • Combined Modality Therapy
  • Coronary Circulation / drug effects*
  • Coronary Circulation / physiology*
  • Coronary Disease / physiopathology
  • Coronary Disease / therapy
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Epinephrine / administration & dosage*
  • Heart Rate / drug effects
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Intra-Aortic Balloon Pumping
  • Michigan
  • Nitroglycerin / therapeutic use
  • Retrospective Studies
  • Syndrome
  • Systole / drug effects
  • Treatment Outcome
  • Vasoconstrictor Agents / administration & dosage*
  • Vasodilator Agents / therapeutic use
  • Verapamil / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Immunoglobulin Fab Fragments
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Verapamil
  • Nitroglycerin
  • Abciximab
  • Epinephrine